This counterintuitive finding suggests that perhaps the inhibitory KIR/KIR-L interaction that would have led to reduced NK anti-tumor cytotoxicity was mitigated by the immunostimulation with dinutuximab, IL-2, and GM-CSF. This evidence concerns the gene CSF2 and neoplasm.